Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Common Equity (2017 - 2025)

Historic Common Equity for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $645.4 million.

  • Protagonist Therapeutics' Common Equity rose 2134.21% to $645.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.4 million, marking a year-over-year increase of 2134.21%. This contributed to the annual value of $675.3 million for FY2024, which is 10057.65% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Common Equity stood at $645.4 million for Q3 2025, which was up 2134.21% from $668.0 million recorded in Q2 2025.
  • Protagonist Therapeutics' Common Equity's 5-year high stood at $689.1 million during Q1 2025, with a 5-year trough of $215.6 million in Q4 2022.
  • For the 5-year period, Protagonist Therapeutics' Common Equity averaged around $407.2 million, with its median value being $329.7 million (2021).
  • As far as peak fluctuations go, Protagonist Therapeutics' Common Equity soared by 31383.53% in 2021, and later crashed by 2836.89% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Common Equity (Quarter) stood at $300.0 million in 2021, then fell by 28.14% to $215.6 million in 2022, then soared by 56.15% to $336.7 million in 2023, then surged by 100.58% to $675.3 million in 2024, then fell by 4.42% to $645.4 million in 2025.
  • Its Common Equity stands at $645.4 million for Q3 2025, versus $668.0 million for Q2 2025 and $689.1 million for Q1 2025.